

of Glasgow

# Bone Health and Body Composition in Childhood Onset Growth Hormone **Deficiency at the Time of Initial Evaluation and Retesting**

NHS Greater Glasgow and Clyde

M Ahmid1, S Shepherd1, M McMillan1, S F Ahmed1, M G Shaikh1

<sup>1</sup>Developmental Endocrinology Research Group, Royal Hospital for Children, School of Medicine, University of Glasgow, Glasgow, UK

# Background

Childhood onset growth hormone deficiency (CO-GHD) may contribute to low bone mass and alterations in bodv composition. However, the direct mechanisms by which CO-GHD effects bone health are not yet clearly defined.

# Objectives


To evaluate musculoskeletal health in CO-GHD subjects at the time of initial evaluation and retesting after final height.

### **Population and Method**

# **Results ctd**

The median of maximum - force (F-max (kN) in naive GHD patients was significantly lower than those who had normal GH levels [0.5 (0.3, 2.8) vs 2.7 (2.2, 3.3) respectively, p= 0.03].

# Figure 2, Scatterplot of muscle strength data



A cross-sectional study of assessing bone health and body composition by imaging (DXA and pQCT), muscle strength by mechanography, and biochemical assessment in children undergoing GH stimulation tests for short stature and biochemical revaluation at final height after GH therapy.

### Results

# Table 1 Auxological and clinical characteristics of first time assessment groups and retesting groups

	First time assessment (n=15)		Retesting (n=11)	
	Naive GHD (n=15)	Normal (n=10)	Persistent GHD (n=7)	GH sufficient (n=4)
M/F	13/2	7/3	3/4	1/3
Age(yrs)	10.9 (5.6, 15.2)	12.1 (5.8, 16.5)	16.6 (14.9, 18.6)	16.8(16.3, 20.4)
Height -SDS	-2.5 (-3.4, 1.3)	-2.2 (-4.6, -0.1)	-1.2 (-1.9, 1.2)	-1.6(-3.0, 0.5)
Weight-SDS	-1.8 (-3.6, 1.9)	-1.3 (-4.7, 0.7)	0.6 (-1.8, 1.4)	0.0(-3.2-1.1)
BMI-SDS	0.0(-1.8-3.0)	0.0 (-2.4, 1.6)	0.9(-1.1, 2.0)	1.0(-1.4- 1.1)
GH-peak(µg/l)	2.6 (0.7, 4.7)	8.0(6.7, 22.3)*	2.0 (0.1, 3.8)	8.3(6.4, 10.2)
IGF1 levels(ng/ml)	65.0 (14.0, 433.0)	85.5(28.0, 295.0)	141.0 (18.0, 294.0)	241.5(117, 327.0)
IGF1 levels SDS	-3.2 (<-5.0, 0.3)	-2.0 (-4.5, -0.9)	-3.2 (<-5.0, -1.3)	-2.0 (-3.5, -0.9)
Retesting data				
Age of childhood diagnosis (yr)			9.5 (2.6, 10.3)	11.4(7.0, 12.0)
Age of start treatment(yr)			10.3 (7.1, 13.6)	11.4(7.0, 12.0)
<b>Duration of childhood rhGH (yr)</b>			4.7 (2.9, 7.8)	8.0 (4.3, 10.2)
Age of stopping rhGH (yr)			15.9 (14.4, 17.9)	17.0(15.7, 20.0)
<b>Duration of stopping</b> rhGH (yr)			0.6(0.2, 1.0)	0.7(0.4, 1.0)

### Maximum-power (kN) with tibia muscle CSA






Figure 3, Correlation between bone parameters with biochemical data


### **CTX levels** and duration of stopping rhGH in retesting



### PTH levels and CTX levels in the retesting



### peak levels and CTX levels in the first time assessment



### **Bone and body composition**


GH deficient did not differ in bone and body composition parameters (as measured by DXA and pQCT) from those who had normal GH levels at time of initial evaluation and retesting

### **PTH levels and CTX levels in** the first time assessment



### after final height.CO-GHD.

Figure-1:Bone resorption marker (CTX) was significantly higher in those with naive GHD compared to normal



### Conclusion

Our results suggest that muscle strength and serum PTH may be an important determinant of bone loss in subjects with CO-GHD.

### **Disclosure Statements: The authors have nothing to disclose**

